Literature DB >> 12162600

Intravenous rifampicin in neonates with persistent staphylococcal bacteraemia.

A Shama1, S K Patole, J S Whitehall.   

Abstract

UNLABELLED: Addition of intravenous rifampin is reported to be useful in prompt clearance of persistent coagulase negative staphylococcal (CONS) bacteraemia in high-risk neonates. Four neonates (mean birthweight 823 g, mean gestation 25 wk) with persistent CONS bacteraemia for > 7-10 d (mean 11) were treated with i.v. rifampicin (10 mg/kg/12 h x 10 d) while continuing vancomycin (15 mg/kg/24 h). Their age at time of infection ranged from 2 to 11 d. The mean (range) vancomycin peak and trough concentrations were 29 (25-35) and 6 (4-10) microg/ml, respectively. The blood isolates were Staphylococcus epidermidis, S. hominis, and S. haemolyticus. Addition of rifampicin was associated with prompt clearance of bacteraemia within 48 h (n = 3) and 5 d (n - 1). Rifampicin-related adverse effects such as abnormal liver function tests and thrombocytopenia did not occur.
CONCLUSION: Addition of i.v. rifampicin to vancomycin may optimize the outcome of persistent CONS bacteraemia and the risk of bacterial resistance related to prolonged exposure to vancomycin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162600     DOI: 10.1080/080352502760069098

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  10 in total

Review 1.  How to manage neonatal tuberculosis.

Authors:  A Di Comite; S Esposito; A Villani; M Stronati
Journal:  J Perinatol       Date:  2015-08-13       Impact factor: 2.521

2.  Persistent coagulase-negative staphylococci bacteremia in very-low-birth-weight infants.

Authors:  Nehama Linder; Adriana Hernandez; Limor Amit; Gil Klinger; Shai Ashkenazi; Itzhak Levy
Journal:  Eur J Pediatr       Date:  2011-01-08       Impact factor: 3.183

3.  Off-label use of antimicrobials in neonates in a tertiary children's hospital.

Authors:  Niina Laine; Ann Marie Kaukonen; Kalle Hoppu; Marja Airaksinen; Harri Saxen
Journal:  Eur J Clin Pharmacol       Date:  2017-01-18       Impact factor: 2.953

4.  Practical approach to catheter-related bloodstream infections in paediatrics.

Authors:  Joan Robinson
Journal:  Paediatr Child Health       Date:  2005-10       Impact factor: 2.253

5.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

6.  Combination of vancomycin and rifampicin for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates.

Authors:  Luciana Rodriguez-Guerineau; María Dolors Salvia-Roigés; Marisol León-Lozano; José Manuel Rodríguez-Miguélez; Josep Figueras-Aloy
Journal:  Eur J Pediatr       Date:  2013-01-18       Impact factor: 3.183

7.  Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.

Authors:  N Margreth van der Lugt; Sylke J Steggerda; Frans J Walther
Journal:  BMC Pediatr       Date:  2010-11-19       Impact factor: 2.125

8.  Duration of vancomycin treatment for coagulase-negative Staphylococcus sepsis in very low birth weight infants.

Authors:  Nehama Linder; Daniel Lubin; Adriana Hernandez; Limor Amit; Shai Ashkenazi
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

9.  Rifampin use and safety in hospitalized infants.

Authors:  Christopher J Arnold; Jessica Ericson; Jordan Kohman; Kaitlyn L Corey; Morgan Oh; Janet Onabanjo; Christoph P Hornik; Reese H Clark; Daniel K Benjamin; P Brian Smith; Vivian H Chu
Journal:  Am J Perinatol       Date:  2015-01-16       Impact factor: 3.079

10.  Antibiotic Treatment of Suspected and Confirmed Neonatal Sepsis Within 28 Days of Birth: A Retrospective Analysis.

Authors:  Jadon S Wagstaff; Robert J Durrant; Michael G Newman; Rachael Eason; Robert M Ward; Catherine M T Sherwin; Elena Y Enioutina
Journal:  Front Pharmacol       Date:  2019-10-15       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.